Alberto Cózar-Llistó

Alberto Cózar-Llistó

Auto-generated profile, based on publicly available information

Alberto Cózar-Llistó

Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JCJavier Cobo
Javier Cobo
EMEsperanza Merino
Esperanza Merino
CMCristina Martínez
Cristina Martínez
ACAlberto Cózar-Llistó
Alberto Cózar-Llistó
ESEvelyn Shaw
Evelyn Shaw
PMPilar Mairal
Pilar Mairal

11 August 2016 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
ACAlberto Cózar-Llistó
Alberto Cózar-Llistó
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
JCJavier Cobo
Javier Cobo
Antibiotic use continues to be the most important risk factor for the development of Clostridium difficile infection (CDI) through disruption of the indigenous microbiota of the colon. This factor, together with environmental contamination, makes hospital and other healthcare facilities the perfect breeding ground for the infection. Several groups of patients are exposed to the hospital environment and, at the same time, affected by conditions that can make CDI more prevalent, more severe or make it present a different clinical picture. The list of such conditions appears too extensive to be reviewed in a single article. Nevertheless, several groups, including the critically ill, oncological patients, solid organ and hematopoietic transplant recipients, patients with inflammatory bowel disease, patients with kidney disease and pregnant women, have generated more attention and have been studied in more detail. On the other hand, pediatric patients constitute a controversial group because the large number of asymptomatic carriers makes interpretation of clinical findings and diagnostic tests difficult, as is the development of an appropriate approach to treatment. We present an in-depth discussion of CDI in these high-risk populations and we also review the issue of CDI in pediatric patients.

1 April 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
ACAlberto Cózar-Llistó
Alberto Cózar-Llistó
FMFernanda Meira
Fernanda Meira
GDGerard Dueñas
Gerard Dueñas
PPPedro Puerta-Alcalde
Pedro Puerta-Alcalde
ASAlex Soriano
Alex Soriano
We aimed to describe changes in characteristics and treatment strategies of hospitalised patients with COVID-19 and detail the mortality trend over time. Observational cohort study of all consecutive patients admitted ≥ 48 h to Hospital Clinic of Barcelona for COVID-19 (1 March–30 September 2020). A total of 1645 consecutive patients with COVID-19 were assessed over a 7-month period. Overall mortality (≤30 days) was 9.7% (159 patients), 7.7% in patients hospitalised in regular wards and 16.7 % in patients requiring ICU admission. Overall mortality decreased from 11.6% in the first month to 1.4% in the last month, reflecting a progressive, significant downward trend (p for trend 700 ng/mL (OR 2.3, CI 1.3–4.1), ferritin>489 ng/mL (OR 1.9; CI 1.5–3.2), C-RP>7 mg/dL (OR 2.6; CI 1.5–4.6), and shorter duration from symptom onset to hospital admission (OR 1.11; CI 1.04–1.17) were factors associated with 30-day mortality at hospital admission. Conversely, hospital admission in the last months (OR 0.80; CI 0.65–0.98) was significantly associated with lower mortality. In-hospital mortality has decreased in patients with COVID-19 over the last, few months, even though main patient characteristics remain similar. Several changes made when managing patients may explain this decreasing trend. Our study provides current data on mortality of patients hospitalised with COVID-19 that might be useful in establishing quality of standard of care. EIT Health, European Union´s Horizon 2020 Research and Innovation Programme), EDRD. PPA [CM18/00132], NGP [FI19/00133], and CGV [FIS PI18/01061], have received grants from Ministerio de Sanidad y Consumo, ISCIII.

8 July 2016 in Progress in Transplantation
Verified
Journal Article
Closed access
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
JOJorge Ortiz
Jorge Ortiz
ÁAÁngel Asensio
Ángel Asensio
RMRocío Martínez-Ruiz
Rocío Martínez-Ruiz
EMElena Múñez
Elena Múñez
VCValentín Cuervas-Mons
Valentín Cuervas-Mons
Background: There is limited knowledge about specific risk factors for Clostridium difficile infection (CDI). Method: A retrospective study comparing cases of CDI in solid organ transplant (SOT) recipients with controls (SOT recipients who did not present CDI). Results: Thirty patients with SOT from 1340 transplantation recipients had at least 1 episode of CDI (2.23%). The accumulated incidence was 3.06% in liver transplantation, 2.78% in lung transplantation, 2.36% in kidney transplantation, and 0.33% in heart transplantation. Seven (23%) cases occurred during the first 2 months. Fifteen (50%) cases were community acquired. Colonoscopy was performed in 6 (20%) cases, but pseudomembranes were observed in only 1 (16%) case. Independent variables found to be related to CDI were previous treatment with proton pump inhibitors (PPIs; odds ratio [OR] 5.5; 95% confidence interval [CI] 1.2-32.0), immunosuppressive regimen including mycophenolate (OR 5.2; 95%CI 1.1-18), hospitalization during the previous 3 months (OR 5.1; 95%CI 1.1-17), and antibiotic treatment during the previous month (OR 6.7; 95%CI 1.4-23). Five (16.7%) patients did not respond to the initial treatment. Recurrences were noted in 6 (20%) patients. Conclusions: Liver transplant recipients presented the highest incidence. Risk factors for CDI were previous treatment with PPIs, immunosuppressive regimen containing mycophenolate, prior hospitalization, and prior antibiotic treatment.

1 January 2016 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
JBJorge Ortiz Balbuena
Jorge Ortiz Balbuena
ÁAÁngel Asensio
Ángel Asensio
IRIsabel Sánchez Romero
Isabel Sánchez Romero
ERElena Múñez Rubio
Elena Múñez Rubio
RRRocío Martínez Ruiz
Rocío Martínez Ruiz
Clinical features of Clostridium difficile infection (CDI) cases diagnosed by detection of polymerase chain reaction (PCR), with negative toxin enzyme immunoassay results (EIA) have not been fully elucidated. The purpose of this study was to determine the magnitude of CDI patients who had negative EIA toxin determinations but positive PCR tests, and their differences in clinical presentation.

1 June 2019 in Anaerobe
Verified
Journal Article
Closed access
ACAlberto Cózar
Alberto Cózar
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
EMEsperanza Merino
Esperanza Merino
C-Cristina Martínez -García
Cristina Martínez -García
ESEvelyn Shaw
Evelyn Shaw
PMPilar Mairal
Pilar Mairal